ID   OV17R
AC   CVCL_2672
SY   OV-17R
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_2672
DR   Cell_Model_Passport; SIDM00476
DR   Cosmic-CLP; 1480361
DR   DepMap; ACH-001373
DR   ECACC; 96020763
DR   EGA; EGAS00001000978
DR   GDSC; 1480361
DR   GEO; GSM711699
DR   GEO; GSM1291145
DR   GEO; GSM1670311
DR   GEO; GSM2474981
DR   PharmacoDB; OV17R_1209_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54936883
RX   PubMed=7707437;
RX   PubMed=25230021;
RX   PubMed=27397505;
RX   PubMed=28273451;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Unspecified (PubMed=25230021).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Met (c.646G>A); ClinVar=VCV000182965; Zygosity=Unspecified (PubMed=25230021; PubMed=28273451; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.39%; Native American=0%; East Asian, North=1.99%; East Asian, South=0%; South Asian=0%; European, North=60.17%; European, South=35.44% (PubMed=30894373).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Cosmic-CLP; DepMap; ECACC; PubMed=25230021
ST   Amelogenin: X
ST   CSF1PO: 11,14
ST   D13S317: 11,13
ST   D16S539: 9,13
ST   D18S51: 13,18
ST   D19S433: 14,16
ST   D21S11: 30
ST   D2S1338: 24,25
ST   D3S1358: 14,17
ST   D5S818: 11
ST   D7S820: 8,10
ST   D8S1179: 13,14
ST   FGA: 21,22
ST   Penta D: 10,13
ST   Penta E: 14
ST   TH01: 9 (Cosmic-CLP; ECACC)
ST   TH01: 9,9.3 (DepMap; PubMed=25230021)
ST   TPOX: 8,10
ST   vWA: 14,18
DI   NCIt; C7700; Ovarian adenocarcinoma
DI   ORDO; Orphanet_213504; Adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=7707437; DOI=10.1093/jnci/87.7.506;
RA   Boocock C.A., Charnock-Jones D.S., Sharkey A.M., McLaren J.,
RA   Barker P.J., Wright K.A., Twentyman P.R., Smith S.K.;
RT   "Expression of vascular endothelial growth factor and its receptors
RT   flt and KDR in ovarian carcinoma.";
RL   J. Natl. Cancer Inst. 87:506-516(1995).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//